CORDIS
EU research results

CORDIS

English EN
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

Objective

Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caused by a multitude of organisms that traditionally evolve various mechanisms of resistance. With time, chronic polymicrobial infection develops, with the most dominant infecting organism being Pseudomonas aeruginosa, which is also important in other infections including wounds, burns and patients with medical devices, making it an important clinical target for the EU. In CF infections, empiric intravenous antibiotics are usually given for two weeks. Recurrent infections and treatments result in increasing antimicrobial resistance, and alterations in pathogen host interactions in the lung and gut flora. Next-generation DNA sequencing technology now offers DNA-based personalised diagnostics and treatment strategies. Enhancing our knowledge of the microbiome allows the use of stratified targeted antibacterial therapy that can be compared with standard empirical antibacterial therapy currently used. We believe this will reduce antibiotic usage, optimize dosage and duration startegies as the therapy will be tailored to the actual individual patient needs. Cystic Fibrosis Microbiome-determined Antimicrobial Therapy Trial in Exacerbations: Results Stratified (CF MATTERS) will provide a randomized multi-centre controlled trial of microbiome-derived antimicrobial treatments versus current empirical therapy. Simultaneously parallel human host-pathogen interaction studies in sputa, human gut microflora analysis and evaluation of murine exacerbation models will be performed. This will improve prescription practice and decrease antimicrobial usage and resistance.

Coordinator

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

Address

Western Road
T12 Yn60 Cork

Ireland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 013 982

Administrative Contact

David O'connell (Dr.)

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

EU Contribution

€ 955 241

UNIVERSITE PARIS DESCARTES

France

EU Contribution

€ 199 638

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 384 410

UNIVERSITY OF WASHINGTON

United States

EU Contribution

€ 490 994

UNIVERSITATSKLINIKUM HEIDELBERG

Germany

EU Contribution

€ 542 038

TEAGASC - AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY

Ireland

EU Contribution

€ 363 797

CLININFO SA

France

EU Contribution

€ 107 962

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 96 264

PAPWORTH HOSPITAL NHS FOUNDATION TRUST

United Kingdom

EU Contribution

€ 219 621

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 132 746

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 224 520

HOSPICES CIVILS DE LYON

France

EU Contribution

€ 82 341

UNIVERSITY HOSPITAL OF SOUTH MANCHESTER NHS FOUNDATION TRUST

United Kingdom

EU Contribution

€ 68 586

ARTTIC

France

EU Contribution

€ 117 608

Project information

Grant agreement ID: 603038

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 June 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 921 629,53

  • EU contribution

    € 5 999 748

Coordinated by:

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

Ireland